Efficacy of Ginkgo biloba tablets as an adjunctive therapy to conventional western medicine in treating cerebral infarction beyond the intravenous thrombolysis time window
10.3760/cma.j.cn341190-20240926-01243
- VernacularTitle:银杏叶片辅助常规西药治疗超静脉溶栓时间窗脑梗死的效果
- Author:
Xiaofang CUI
1
Author Information
1. 巴彦淖尔市医院中医内科，巴彦淖尔 015000
- Publication Type:Journal Article
- Keywords:
Brain infarction;
Hemodynamics;
Oxidative Stress;
Treatment Outcome;
Catalase;
Malondialdehyde
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(8):1142-1146
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of Ginkgo biloba tablets as an adjunctive therapy to conventional western medicine in treating cerebral infarction beyond the intravenous thrombolysis time window.Methods:A total of 96 patients with cerebral infarction beyond the intravenous thrombolysis time window who were treated at Bayannur Hospital from December 2021 to December 2023 were included in this study. Using the random digital table method, these patients were assigned to an observation group and a control group ( n = 48 per group). The control group received conventional Western medicine treatment, while the observation group received Ginkgo biloba tablets in addition to conventional Western medicine. Cerebral hemodynamics, oxidative stress indicators, and levels of nerve injury markers were measured and compared between the two groups. Additionally, the neurological deficits and self-care abilities of the patients were assessed, and any adverse reactions, such as gastrointestinal discomfort and gingival bleeding, were recorded throughout the treatment period. Results:After treatment, the average blood flow velocities of the anterior, middle, and posterior cerebral arteries in the observation group were significantly higher than those in the control group [(50.31 ± 5.22) cm/s vs. (43.25 ± 4.47) cm/s, (60.82 ± 6.14) cm/s vs. (52.63 ± 5.31) cm/s, (44.97 ± 4.63) cm/s vs. (39.85 ± 4.02) cm/s, t = -7.12, -6.99, -5.78, all P < 0.001]. Additionally, the serum catalase levels in the observation group were significantly higher than those in the control group, while the malondialdehyde levels were significantly lower in the observation group [(124.03 ± 12.74) U/mL vs. (104.25 ± 11.01) U/mL, (3.11 ± 0.32) mmol/L vs. (4.02 ± 0.43) mmol/L, t = -8.14, 11.76, both P < 0.001]. The levels of S100β protein and neuron-specific enolase in the observation group were also significantly lower than those in the control group ( t = 9.32, 17.32, both P < 0.001). The National Institutes of Health Stroke Scale scores in the observation group were significantly lower than those in the control group, and Barthel Index scores in the observation group were significantly higher than those in the control group ( t = 17.46, -9.09, both P < 0.001). There was no statistically significant difference in the overall incidence of adverse reactions, such as gastrointestinal discomfort and rashes, between the two groups ( χ2 = 0.38, P > 0.05). Conclusions:The use of Ginkgo biloba tablets as an adjunctive therapy to conventional Western medicine in patients with cerebral infarction beyond the thrombolysis time window can promote the recovery of cerebral hemodynamics, reduce oxidative stress responses, and provide neuroprotective effects. This treatment can improve patients' neurological function and self-care abilities while ensuring high safety.
